AOL Money & Finance

Feed

Chasing Value: Ten stocks for 2010 -- Part 5

The march toward year end continues as three more stocks are reviewed in a search for the eventual 2010 stock picks. This year there will be nine stocks with a new wrinkle, I will add one naked put.

These options have contributed to a mind-boggling return on my 2009 portfolio, exceeding 200% to date. This has been a very unusual year, and I bet against the rampant fear in the market. I will not pretend for a moment that this is repeatable. What I will do is share my opinions and investing adventure, hoping to stimulate investor interest and dialog.

Continue reading Chasing Value: Ten stocks for 2010 -- Part 5

Cramer on BloggingStocks: Pelosi can't kill the health care sector

TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge.

Nancy Pelosi has now said her piece. The most unpopular Speaker of the House in the history of Wall Street has gotten her precious health care legislation through the House after ramming through a stimulus package that had far too little infrastructure and far too much pay raise for municipal and state workers, the most powerful interest group in the country.

But this time the Senate sees through it, and the politicians -- despite Pelosi's insistence that Tuesday's election went her way -- know better. There are pages after pages after pages in this bill that look threatening. But here's the rub: This bill's public option, the one that is supposed to be a killer to everything health care, should affect no more than 6 million people over a 10-year period, according to the Congressional Budget Office. In order to get 60 votes in the Senate, even that may prove to be too powerful an option.

Continue reading Cramer on BloggingStocks: Pelosi can't kill the health care sector

Earnings highlights: C, GE, GOOG, HOG, INTC, IBM, JNJ, JPM, MAT, NOK ...

Here are some highlights from last week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: C, GE, GOOG, HOG, INTC, IBM, JNJ, JPM, MAT, NOK ...

Abbott Laboratories posts solid earnings results

Plenty of companies are reporting earnings this Wednesday morning, one of which is Abbott Laboratories (NYSE: ABT).

The health-care giant reported third-quarter earnings of 95 cents per share, far better than last year's 69 cents per share. Taking items out of the equation, Abbott would have earned 92 cents per share, which is two cents better than the consensus estimate. Quarterly revenue matched the consensus estimate for $7.76 billion.

Continue reading Abbott Laboratories posts solid earnings results

Earnings preview: Abbott Labs Q3 acquisitions to pay off?

Abbott Laboratories (NYSE: ABT), the broad-based health care company that produces both Humira and Similac, is scheduled to discuss its third quarter 2009 financial results in a conference call Wednesday at 9:00 AM ET. You can catch the live webcast on the company's website.

During the three months that ended in September, Abbott Labs announced acquisitions of Visiogen, Evalve, and Solvay pharmaceuticals, as well as declared its 343rd consecutive quarterly dividend. Analysts surveyed by Thomson Reuters expect this suburban Chicago company to report that earnings rose 12.2% from a year ago to $0.90 per share. Sales for the quarter are expected to be 3.3% higher to $7.8 billion.

Continue reading Earnings preview: Abbott Labs Q3 acquisitions to pay off?

Turnaround expert targets laggard pharmaceuticals

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Continue reading Turnaround expert targets laggard pharmaceuticals

Week in preview: Goldman Sachs, JPMorgan, Google, IBM and more earnings

Goldman Sachs upgraded the banking sector last week, and this coming week we'll get a chance to see whether Goldman and other big banks reporting third quarter results will live up to the expectations of analysts surveyed by Thomson Reuters.

New York-based Goldman Sachs Group Inc. (NYSE: GS) looks set to be this week's earnings game winner. Analysts expect this dividend-paying company to report a third-quarter profit of $4.24 per share, which is 57.3% higher than in the same period of last year. Revenue for the period that ended in September is expected to be $11.0 billion. So far, the full-year forecast is for $17.74 per share on $44.6 billion.

Continue reading Week in preview: Goldman Sachs, JPMorgan, Google, IBM and more earnings

Closing bell: M&A gives market a boost; Coffee also provides stimulus (C, BAC, ACS, DDRX & GMCR)

Traders had on their rally caps today, and the DJIA moved as high as 9,823 as it renewed its ascent toward 10,000. The index moved back down a bit at the end of the day as traders got lazy during a session in which most of the news came before the bell.

Abbott Laboratories (NYSE: ABT) and Xerox Corporation (NYSE: XRX) both announced deals today that pumped some air into the M&A business. Financial shares are mostly moving higher because increased M&A activity generally means more fees for financial services companies. Trading volume was light, mostly due to the Yom Kippur holiday today.

Today's numbers:

Dow 9,789.44 +124.25 (1.29%)
S&P 500 1,062.88 +18.50 (1.77%)
Nasdaq 2,130.74 +39.82 (1.90%)

Continue reading Closing bell: M&A gives market a boost; Coffee also provides stimulus (C, BAC, ACS, DDRX & GMCR)

Before the bell: Investors bullish ahead of new reports

Stocks are expected to open modestly higher on Wall Street after a losing week last week. On Friday, stocks fell for the third straight day after reports on new-home sales and durable goods proved weaker than expected, leading investors to believe the economy has not yet emerged from the recession.

Stocks to watch today include pharmaceutical giant Johnson & Johnson (NYSE: JNJ), which agreed Monday to buy an 18% stake in European drug maker Crucell (NASDAQ: CRXL) for 301.8 million euros ($440 million), as part of a deal to develop flu vaccines.

Continue reading Before the bell: Investors bullish ahead of new reports

Vita Nelson: DRIP expert votes for Abbott (ABT)

In her The MoneyPaper, editor Vita Nelson looks to stocks offering dividend reinvestment plans. Here, she highlights Abbott Laboratories (NYSE: ABT) as a featured holding in her model portfolio.

"Abbott is a diversified, multinational, health care firm.The shares have not responded to the recent stock market rallies in part due to the defensive nature of health care stocks.

"Uncertainty regarding health care reform is also a factor in the static share price of recent months. ABT shares are now trading below 11 times 2010 earnings estimates, compared with about 15 for the S&P 500.

Continue reading Vita Nelson: DRIP expert votes for Abbott (ABT)

Health care questions (rip-off) abound -- ABT, JNJ, NVS & TEVA

One of the complaints we often hear is that the private insurance companies are gouging customers, second guessing doctors, and cutting corners at every turn to increase profit margins. A great deal of this is true and I would not debate that this dilutes the quality of health care in the United States.

Is the corollary that the government intends to run a health care program that does not make a profit?

That is a very probable outcome. If that is the case then how is it possible that the government will be able to fund something that is a money loser from the get go?

Continue reading Health care questions (rip-off) abound -- ABT, JNJ, NVS & TEVA

Cramer on BloggingStocks: The health care bargain

TheStreet.com's Jim Cramer says health care has never been this cheap relative to the market in its history.

Health care's not done rallying. As President Obama prepared himself for claiming a great political victory, we are all recognizing that the single-payer, socialized medicine covering cradle-to-grave, 100% paid for by the rich, the fear that left all things health care in the P/E dustbin, is dead. That's not going to happen.

That leaves us with the biggest bargains the market has to offer.

Health care has never been this lowly valued relative to the market in its history. Remember, 98% of the time it trades at a meaningful premium. I think that many believe some of these moves (like the Celgene (NASDAQ: CELG) (Cramer's Take) move) is because of gigantic new drug finds. In fact, I think they just got too cheap and the only thing really meaningful about the Celgene rally came because one of its Revlimid studies was stopped for good results, actually a predictable event given how well the drug works on many different kinds of cancers.

Continue reading Cramer on BloggingStocks: The health care bargain

Health Care's costs & the misguided debate

In recent stories I have highlighted several health care stocks that I think would be strong candidates for small portfolios (Part 1 and Part 2) that would be safe and pay high yields. These include: Johnson and Johnson (NYSE: JNJ), Abott Laboratories (NYSE: ABT) and Novartis AG ADS (NYSE: NVS). I have been thinking about these companies and how others will fare in the health care debate.

While Washington debates the merits of various health care bills, the health care companies lobby to influence the outcome. Businesses and employees are resistant to taxing current health care benefits but very few people are opposed to taxing those that get big paychecks.

I think we are heading down the wrong path regarding health care "reform" once again. There is no question that most people want to improve health care in many respects, including but not limited to, the quality, cost, and delivery, but the devil is in the details and we may end up no better off than we started except of course with more complexity and greater cost.

Continue reading Health Care's costs & the misguided debate

Serious Money: Five more high yield, safe, diversified stocks -- Part 2

The market may be entering a more volatile period or it may just go sideways for a while. The last few weeks the market has been down. Maybe it is because the rapid rise mid-March through mid-June is forcing people to stop and take a breath, or perhaps it is because investors are having second thoughts about whether the "green shoots" Ben Bernanke spoke of in regards to a healing economy were really just weeds.

All in all, I still believe that there is opportunity in this market and I have been trying to point out how investors can get in with as little risk as possible, while being rewarded for their patience now, and when a recovery ensues ---- whenever that is. To this end, two weeks ago I posted Serious Money: Five high-yield, safe, diversified stocks and decided to follow up with another five I think will produce similar results.

Continue reading Serious Money: Five more high yield, safe, diversified stocks -- Part 2

Abbott Labs to pay J&J $1.67 billion from patent lawsuit

Yesterday, pharmaceutical giant Johnson & Johnson (JNJ) said that its patent infringement lawsuit against Abbott Labs (ABT) was successful, with Abbott ordered to pay $1.67 billion because its best-selling drug, Humira, too closely resembles J&J's Remicade. The drugs are intended to treat rheumatoid arthritis by blocking a substance known as TNF, which causes inflammation. According to the Arthritis Foundation, 1.3 million Americans suffer from rheumatoid arthritis, a chronic disease. Abbott Labs sponsors the group's programs specifically related to rheumatoid arthritis.

The verdict leaves Abbott stock in a tenuous position. The healthcare sector has been in the crosshairs lately as concerns about costly medical reform swirl, with the SPDR S&P Pharmaceuticals (XPH) ETF down slightly year-to-date, compared to the nearly 5% gain on the S&P 500. Abbott Labs has underperformed both comparables, and is down 10% year-to-date.

Continue reading Abbott Labs to pay J&J $1.67 billion from patent lawsuit

Next Page »

Symbol Lookup
IndexesChangePrice
DJIA+30.6910,464.40
NASDAQ+6.872,176.05
S&P 500+4.981,110.63

Last updated: November 26, 2009: 02:33 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance